{
    "text_blocks": {
        "data": {
            "block_count": 1,
            "table_index": 0
        },
        "model": null,
        "timestamp": "2025-01-21_09-41-35"
    },
    "table_comments": {
        "data": "CONSOLIDATED BALANCE SHEET\t(Unaudited)\tApril 2,\tDecember 31,\t(In millions except share and per share amounts)\t2022\t2021\t",
        "timestamp": "2025-03-11_12-45-23"
    },
    "units": {
        "data": {
            "sum_units": 1000000,
            "sum_divider": 1.0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1000000",
                    "1": "1000000"
                },
                "decision": "1000000"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-45-26"
    },
    "post_table_text": {
        "data": "\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3",
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "'\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3'"
                },
                "decision": "'\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3'"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-45-28"
    },
    "table_body": {
        "data": "Assets\tCurrent assets:\tCash and cash equivalents\t$\t2,752\t$\t4,477\tAccounts receivable, less allowances of $\t170\tand $\t150\t7,889\t7,977\tInventories\t5,483\t5,051\tContract assets, net\t1,064\t968\tOther current assets\t1,588\t1,640\tTotal current assets\t18,776\t20,113\tProperty, plant and equipment, net\t8,448\t8,333\tAcquisition-related intangible assets, net\t19,378\t20,113\tOther assets\t4,424\t4,640\tGoodwill\t41,721\t41,924\tTotal assets\t$\t92,747\t$\t95,123\tLiabilities, redeemable noncontrolling interest and equity\tCurrent liabilities:\tShort-term obligations and current maturities of long-term obligations\t$\t1,866\t$\t2,537\tAccounts payable\t2,667\t2,867\tAccrued payroll and employee benefits\t1,634\t2,427\tContract liabilities\t2,871\t2,655\tOther accrued expenses\t3,032\t2,950\tTotal current liabilities\t12,070\t13,436\tDeferred income taxes\t3,493\t3,837\tOther long-term liabilities\t4,664\t4,540\tLong-term obligations\t31,389\t32,333\tRedeemable noncontrolling interest\t113\t122\tEquity:\tThermo Fisher Scientific Inc. shareholders  equity:\tPreferred stock, $\t100\tpar value,\t50,000\tshares authorized;\tnone\tissued\tCommon stock, $\t1\tpar value,\t1,200,000,000\tshares authorized;\t439,530,820\tand\t439,154,741\tshares issued\t440\t439\tCapital in excess of par value\t16,292\t16,174\tRetained earnings\t37,528\t35,431\tTreasury stock at cost,\t48,068,820\tand\t44,720,112\tshares\t(\t10,961\t)\t(\t8,922\t)\tAccumulated other comprehensive items\t(\t2,343\t)\t(\t2,329\t)\tTotal Thermo Fisher Scientific Inc. shareholders  equity\t40,956\t40,793\tNoncontrolling interests\t62\t62\tTotal equity\t41,018\t40,855\tTotal liabilities, redeemable noncontrolling interest and equity\t$\t92,747\t$\t95,123",
        "timestamp": "2025-03-11_12-45-28"
    },
    "table_json_created": {
        "data": true,
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [2752, 4477], \"Accounts receivable, less allowances of $ 170 and $ 150\": [7889, 7977], \"Inventories\": [5483, 5051], \"Contract assets, net\": [1064, 968], \"Other current assets\": [1588, 1640], \"Total current assets\": [18776, 20113]}, \"Property, plant and equipment, net\": [8448, 8333], \"Acquisition-related intangible assets, net\": [19378, 20113], \"Other assets\": [4424, 4640], \"Goodwill\": [41721, 41924], \"Total assets\": [92747, 95123]}, \"Liabilities, redeemable noncontrolling interest and equity\": {\"Current liabilities\": {\"Short-term obligations and current maturities of long-term obligations\": [1866, 2537], \"Accounts payable\": [2667, 2867], \"Accrued payroll and employee benefits\": [1634, 2427], \"Contract liabilities\": [2871, 2655], \"Other accrued expenses\": [3032, 2950], \"Total current liabilities\": [12070, 13436]}, \"Deferred income taxes\": [3493, 3837], \"Other long-term liabilities\": [4664, 4540], \"Long-term obligations\": [31389, 32333], \"Redeemable noncontrolling interest\": [113, 122], \"Equity\": {\"Thermo Fisher Scientific Inc. shareholders equity\": {\"Preferred stock, $ 100 par value, 50,000 shares authorized; none issued\": [0, 0], \"Common stock, $ 1 par value, 1,200,000,000 shares authorized; 439,530,820 and 439,154,741 shares issued\": [440, 439], \"Capital in excess of par value\": [16292, 16174], \"Retained earnings\": [37528, 35431], \"Treasury stock at cost, 48,068,820 and 44,720,112 shares\": [-10961, -8922], \"Accumulated other comprehensive items\": [-2343, -2329], \"Total Thermo Fisher Scientific Inc. shareholders equity\": [40956, 40793]}, \"Noncontrolling interests\": [62, 62], \"Total equity\": [41018, 40855]}, \"Total liabilities, redeemable noncontrolling interest and equity\": [92747, 95123]}}"
                },
                "decision": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [2752, 4477], \"Accounts receivable, less allowances of $ 170 and $ 150\": [7889, 7977], \"Inventories\": [5483, 5051], \"Contract assets, net\": [1064, 968], \"Other current assets\": [1588, 1640], \"Total current assets\": [18776, 20113]}, \"Property, plant and equipment, net\": [8448, 8333], \"Acquisition-related intangible assets, net\": [19378, 20113], \"Other assets\": [4424, 4640], \"Goodwill\": [41721, 41924], \"Total assets\": [92747, 95123]}, \"Liabilities, redeemable noncontrolling interest and equity\": {\"Current liabilities\": {\"Short-term obligations and current maturities of long-term obligations\": [1866, 2537], \"Accounts payable\": [2667, 2867], \"Accrued payroll and employee benefits\": [1634, 2427], \"Contract liabilities\": [2871, 2655], \"Other accrued expenses\": [3032, 2950], \"Total current liabilities\": [12070, 13436]}, \"Deferred income taxes\": [3493, 3837], \"Other long-term liabilities\": [4664, 4540], \"Long-term obligations\": [31389, 32333], \"Redeemable noncontrolling interest\": [113, 122], \"Equity\": {\"Thermo Fisher Scientific Inc. shareholders equity\": {\"Preferred stock, $ 100 par value, 50,000 shares authorized; none issued\": [0, 0], \"Common stock, $ 1 par value, 1,200,000,000 shares authorized; 439,530,820 and 439,154,741 shares issued\": [440, 439], \"Capital in excess of par value\": [16292, 16174], \"Retained earnings\": [37528, 35431], \"Treasury stock at cost, 48,068,820 and 44,720,112 shares\": [-10961, -8922], \"Accumulated other comprehensive items\": [-2343, -2329], \"Total Thermo Fisher Scientific Inc. shareholders equity\": [40956, 40793]}, \"Noncontrolling interests\": [62, 62], \"Total equity\": [41018, 40855]}, \"Total liabilities, redeemable noncontrolling interest and equity\": [92747, 95123]}}"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-12_11-47-09"
    },
    "problems": {
        "data": [],
        "timestamp": "2025-03-12_11-47-09"
    }
}